LAB
Standard Biotools Inc
0.7698$
+5.5%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 38.3% | 38.8% | 31.6% | 33.0% | 41.9% | 36.3% | 36.2% | 26.2% | 53.5% | 49.0% | 61.4% | 80.0% | |
| 8.3% | 7.8% | 11.4% | 20.2% | 31.4% | 8.2% | 21.1% | 10.3% | 20.8% | 16.0% | 27.2% | 20.8% | |
| 28.3% | 25.6% | 19.4% | 22.0% | 31.4% | 22.1% | 21.1% | 10.3% | 42.5% | 35.6% | 47.8% | 33.0% | |
| 5.5% | 6.9% | 4.8% | 5.2% | 5.5% | 7.2% | 7.8% | 6.7% | 4.4% | 6.1% | 5.5% | 2.4% | |
| 3.9% | 4.8% | 6.6% | 5.3% | 4.3% | 5.2% | 6.1% | 7.6% | 5.5% | 6.4% | 6.7% | 3.5% | |
| – | – | 5.4% | 4.3% | 2.9% | 4.9% | 17.1% | 23.7% | 15.3% | – | – | – | |
| 25.5% | 28.1% | 34.0% | 36.2% | 34.3% | 39.3% | 32.8% | 38.7% | 27.2% | 32.9% | 18.2% | – | |
| 25.1% | 24.5% | 26.0% | 23.9% | 18.9% | 18.6% | 13.0% | 10.1% | 3.2% | 0.4% | 4.7% | – | |
| 63.1% | 69.0% | 82.6% | 89.2% | 76.3% | 42.0% | 57.2% | 65.6% | 120.9% | 145.8% | 23.0% | 25.3% | |
| 7.2% | 8.1% | 9.6% | 11.6% | 12.4% | 12.4% | 16.7% | 18.0% | 11.1% | 33.8% | 10.8% | 19.1% | |
| – | – | 0.0% | 0.0% | 0.0% | 0.7% | 0.9% | 3.6% | 1.5% | 19.8% | 1.0% | 1.0% | |
| 1.5% | 1.6% | 1.3% | 1.5% | 1.3% | 1.9% | 2.8% | 3.9% | 2.0% | 2.9% | 2.0% | 1.0% | |
| – | – | 63.6% | 67.9% | 56.7% | 20.3% | 16.7% | 23.3% | 16.1% | 1.2% | 0.0% | 0.1% | |
| 36.9% | 31.0% | 17.4% | 10.8% | 23.7% | 58.0% | 42.8% | 34.4% | -20.9% | -45.8% | 77.0% | 74.7% | |
| -76.1% | -98.0% | -143.4% | -174.1% | -184.0% | -235.5% | -208.4% | -267.4% | -237.3% | -309.8% | -193.6% | -222.0% | |
| 6.8% | 7.7% | 9.5% | 11.5% | 13.1% | 25.2% | 22.2% | 27.5% | 20.1% | 24.5% | 57.6% | 67.2% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.